Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results

SAN FRANCISCO, Feb. 28, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2012.

Cash, cash equivalents, and investments at December 31, 2012 were $302.2 million as compared to $414.9 million at December 31, 2011.

"As we enter 2013, Nektar is in an excellent position with five highly valuable late-stage programs across multiple therapeutic areas," said Howard W. Robin, President and Chief Executive Officer of Nektar. "With positive efficacy and safety results from the full Phase 3 KODIAC program for naloxegol, our partner AstraZeneca is preparing to submit registration filings in the U.S. and EU in the third quarter of this year.  We are tremendously pleased that Bayer is scheduled to start the Phase 3 program next month for Amikacin Inhale in gram-negative pneumonia.  Additionally, we expect to report key Phase 2 clinical data this summer for NKTR-181, our novel opioid analgesic, which represents a potential breakthrough for the treatment of chronic pain."

Revenue for the fourth quarter of 2012 was $21.1 million as compared to $15.8 million in the fourth quarter of 2011. Revenue for the year ended December 31, 2012 was $81.2 million as compared to $71.5 million in 2011.  2012 revenue included $10.8 million in non-cash revenues resulting from the $124 million sale of future royalties related to Cimzia® and Mircera®, which was completed in February 2012.  This non-cash royalty revenue is offset by non-cash interest expense.  For both the quarter and the year ended December 31, 2012, product sales increased significantly.  These increases were partially offset by decreases in royalty revenues.

Total operating costs and expenses in the fourth quarter of 2012 were $64.5 million as compared to $50.3 million in the fourth quarter of 2011.  Total operating costs and expenses for the year ended December 31, 2012 were $222.4 million as compared to $195.4 million in 2011.  The increases in 2012 as compared to 2011 are due primarily to increased clinical development expenses as well as higher cost of goods related to increased product sales.

Research and development expense in the fourth quarter of 2012 was $46.4 million as compared to $33.3 million for the fourth quarter of 2011.  For the year ended December 31, 2012, R&D expense was $148.7 million as compared to $126.8 million in 2011. R&D expense was higher in the fourth quarter and year ended December 31, 2012 as compared to the same periods in 2011 reflecting the costs of the etirinotecan pegol (NKTR-102) BEACON Phase 3 study, the production of devices for the Phase 3 study of Amikacin Inhale, the Phase 1 and Phase 2 studies for NKTR-181, and the Phase 1 study for NKTR-192. 

General and administrative expense was $10.9 million in the fourth quarter of 2012 as compared to $11.5 million in the fourth quarter of 2011.  G&A expense for the year ended December 31, 2012 was $41.6 million as compared to $46.8 million in 2011.

Non-cash interest expense was $5.4 million and $18.1 million in the fourth quarter and year ended December 31, 2012, respectively.  The company incurred non-cash interest expense as a result of the sale of future royalties related to Cimzia® and Mircera®.  No non-cash interest expense was incurred in 2011.

Net loss for the fourth quarter ended December 31, 2012 was $52.9 million or $0.46 loss per share.  Net loss for the year ended December 31, 2012 was $171.9 million or $1.50 loss per share.  Net loss for the fourth quarter ended December 31, 2011 was $37.5 million or $0.33 loss per share.  Net loss for the year ended December 31, 2011 was $134.0 million or $1.19 loss per share.

The company also announced upcoming presentations at the following medical meetings and scientific congresses during the first half of 2013:

33rd International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium:

  • Poster P081: "In Vitro Efficiency of the Amikacin Inhale System, A Novel Integrated Drug-Device Delivery System", Kadrichu, N., et al. 
  • Date: March 19, 2013
  • American Association for Cancer Research 2013 Annual Meeting, Washington, DC:

  • Abstract #482: "Tipping the Balance in the Tumor Microenvironment: An Engineered Cytokine (NKTR-214) with Altered IL-2 Receptor Binding Selectivity and Improved Efficacy in a Mouse Melanoma Model", Charych, D., et al. 
  • Date: April 7, 2013, 1:00 p.m. — 5:00 p.m. Eastern Time
  • Poster Session: Immunology 2
  • Abstract #2475: "A new polymer conjugated taxane shows improved efficacy in tumor xenograft models", Fry, D., et al.
  • Date: April 9, 2013, 8:00 a.m. — 12:00 p.m. Eastern Time
  • Poster Session: Chemistry 4
  • American Academy of Pain Medicine 29th Annual Meeting, Fort Lauderdale, FL:

  • Poster #115 : "New Oral Opioid Analgesic NKTR-181 Demonstrates Analgesic Response in Cold Pressor Test in Healthy Subjects", Eldon, M., et al. 
  • Date: April 11, 2013, 5:15 p.m. — April 12, 2013 10:30 a.m. Eastern Time
  • American Pain Society 32nd Annual Scientific Meeting, New Orleans, LA:

  • Poster: "NKTR-171: A Novel, Oral Sodium Channel Blocker That Exhibits Comparable Analgesic Efficacy to Pregabalin with Reduced Central Nervous System (CNS) Side Effects", Gursahani, H., et al. 
  • Date: May 9, 2013, 9:30 a.m. Eastern Time
  • Digestive Disease Week 2013, Orlando, FL:

  • Abstract 1594557: "Efficacy and Safety of Naloxegol in Patients with Opioid-Induced Constipation: Results from 2 Prospective, Randomized, Controlled Trials", Chey, W., et al. 
  • Date: May 21, 2013, 8:15 a.m. Eastern Time
  • Research Forum: New Pharmacological Treatments for Motility Disorders
  • 4th International Congress on Neuropathic Pain, Toronto, Canada:

  • Poster A-484-0002-00647: "NKTR-171: Preclinical Efficacy and Improved Central Nervous System (CNS) Side Effect Profile of a Novel Sodium Channel Blocker Designed for the Treatment of Neuropathic Pain", Gursahani, H., et al. 
  • Date: May 25, 2013, 1:30 p.m. – 3:30 p.m. Eastern Time
  • Poster Session II
  • College on Problems of Drug Dependence 75th Annual Meeting, San Diego, CA:

  • Poster 1598130: "Opioids With Lower Brain Uptake Are Less Recognizable in Rat Drug Discrimination Tests and thus Potentially Less Subject to Abuse", Harrison, S., et al. 
  • Date: June 19, 2013, 12:00 p.m. – 2:00 p.m. Pacific Time
  • Poster 1605508: "Abuse Potential Assessment of Novel Opioid Analgesic NKTR-181: Implications for Labeling", Webster, L., et al. 
  • Date: June 20, 2013, 7:30 a.m. – 9:30 a.m. Pacific Time
  • Conference Call to Discuss Fourth Quarter and Year-End 2012 Financial ResultsNektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time today, Thursday, February 28, 2013.

    This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: The web broadcast of the conference call will be available for replay through Friday, March 15, 2013.

    To access the conference call, follow these instructions:

    Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)
    Passcode: 98224860 (Nektar Therapeutics is the host)

    In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

    About Nektar
    Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

    Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

    Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at

    Cautionary Note Regarding Forward-Looking Statements
    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential future regulatory filings by AstraZeneca for naloxegol; the projected timing of the start of the Phase 3 clinical study by Bayer for Amikacin Inhale; the projected availability of Phase 2 clinical study results for NKTR-181; and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) acceptance, review and approval decisions for new drug applications by health authorities is an uncertain and evolving process and health authorities retain significant discretion at all stages of the regulatory review and approval decision process; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; and (v) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2012. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

    (415) 482-5585Susan Noonan/SA Noonan Communications, LLC

    (212) 966-3650 

    Nektar Media Inquiries:Amanda Connelly/MSL

    (404) 870-6865Mike Huckman /MSL

    (646) 500-7631 NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSDecember 31, 2012December 31, 2011

    (1)Current assets:Cash and cash equivalents

    5,312Short-term investments

    251,757225,856Accounts receivable, net


    18,26912,656Other current assets

    13,36317,944Total current assets

    314,631276,706Long-term investments

    -173,768Restricted cash

    25,000-Property and equipment, net


    76,50176,501Other assets

    9,443999Total assets

    ,550LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    3,019Accrued compensation

    8,77312,807Accrued expenses

    8,0086,669Accrued clinical trial expenses

    17,50011,953Deferred revenue, current portion

    21,89619,643Interest payable

    7,0831,805Convertible subordinated notes

    -214,955Other current liabilities

    12,4144,681Total current liabilities

    78,537275,532Senior secured notes

    125,000-Capital lease obligations, less current portion

    11,60714,582Liability related to sale of future royalties, less current portion

    128,266-Deferred revenue, less current portion

    96,551108,188Deferred gain

    2,4043,278Other long-term liabilities

    8,4077,159Total liabilities

    450,772408,739Commitments and contingenciesStockholders' equity:Preferred stock

    --Common stock

    1111Capital in excess of par value

    1,617,7441,597,428Accumulated other comprehensive loss

    (357)(1,103)Accumulated deficit

    (1,570,380)(1,398,525)Total stockholders' equity

    47,018197,811Total liabilities and stockholders' equity

    ,550(1) The consolidated balance sheet at December 31, 2011 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements.  NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share information)(Unaudited)Three Months EndedTwelve Months EndedDecember 31,December 31,2012201120122011Revenue:  Product sales

    $  10,405$
    24,864  Royalty revenues

    9083,0954,87410,327  Non-cash royalty revenue related to sale of future royalties

    3,896-10,791-  License, collaboration and other

    5,9376,61430,12736,289Total revenue

    21,14615,78281,19171,480Operating costs and expenses:  Cost of goods sold

    7,2905,45030,42821,891  Research and development

    46,37333,302148,675126,766  General and administrative

    10,86411,49841,61446,760  Impairment of long-lived assets

    --1,675-Total operating costs and expenses

    64,52750,250222,392195,417Loss from operations

    (43,381)(34,468)(141,201)(123,937)Non-operating income (expense):  Interest income 

    4506612,3152,244  Interest expense

    (4,682)(2,525)(15,489)(10,223)  Non-cash interest expense on liability related to sale of future royalties

    (5,416)-(18,057)-  Other income (expense), net

    70(445)983(1,044)Total non-operating expense, net

    (9,578)(2,309)(30,248)(9,023)Loss before provision for income taxes

    (52,959)(36,777)(171,449)(132,960)Provision (benefit) for income taxes

    (33)7184061,018Net loss

    $ (52,926)$ (37,495)$ (171,855)$ (133,978)Basic and diluted net loss per share

    (1.19)Weighted average shares outstanding used in computing basic and diluted net loss per share115,179114,446114,820112,942 NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Twelve Months Ended December 31,20122011Cash flows from operating activities:Net loss 

    (133,978)Adjustments to reconcile net loss to net cash used in operating activities:Non-cash interest expense on liability related to sale of future royalties 

    18,057-Non-cash royalty revenue related to sale of future royalties

    (10,791)-Stock-based compensation 

    16,19918,885Depreciation and amortization 

    14,50814,951Impairment of long-lived assets

    1,675-Other non-cash transactions

    8451,359Changes in operating assets and liabilities:Accounts receivable


    (5,613)(5,390)Other assets

    6,031(12,267)Accounts payable

    (122)(3,384)Accrued compensation

    (4,034)3,555Accrued expenses

    1,4951,013Accrued clinical trial expenses

    5,547(191)Deferred revenue

    (9,384)(17,516)Interest payable

    5,278-Other liabilities

    3,275(943)Net cash used in operating activities 

    (129,756)(113,742)Cash flows from investing activities:Purchases of property and equipment 

    (10,583)(9,722)Restricted cash

    (25,000)-Maturities of investments 

    307,887383,052Sales of investments 

    5,378210,089Purchases of investments 

    (164,662)(695,371)Net cash provided by (used in) investing activities 

    113,020(111,952)Cash flows from financing activities:Proceeds from issuance of senior secured notes, net

    77,940-Repayment of convertible subordinated notes

    (172,407)-Payment of capital lease obligations

    (2,437)(1,978)Proceeds from sale of future royalties, net

    119,588-Proceeds from shares issued under equity compensation plans

    4,1174,530Issuance of common stock, net

    -219,783Net cash provided by financing activities 

    26,801222,335Effect of exchange rates on cash and cash equivalents 

    60916Net increase (decrease) in cash and cash equivalents 

    10,125(2,443)Cash and cash equivalents at beginning of period

    15,31217,755Cash and cash equivalents at end of period

    5,312Supplemental disclosure of cash flow information:Cash paid for interest

    ,277Cash paid for income taxes

    957Supplemental schedule of non-cash investing and financing activities:Retirement of convertible subordinated notes in exchange for senior secured notes


    SOURCE Nektar Therapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
    2. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
    3. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
    4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
    5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
    6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
    7. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
    8. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
    9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
    10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
    11. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
    Post Your Comments:
    (Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
    (Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at ...
    (Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
    (Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
    (Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
    Breaking Medicine News(10 mins):